The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Outcomes of patients with triple-class refractory myeloma: a single-center retrospective study
James Berenson, MD, Berenson Cancer Center, West Hollywood, CA, shares insights into a single-center retrospective study evaluating the outcomes of patients with triple-class refractory multiple myeloma, highlighting the promise of novel agents and combinations in this patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Incyte Corporation
